Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Up 8.0% in December

Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 1,080,000 shares, a growth of 8.0% from the November 30th total of 1,000,000 shares. Based on an average daily volume of 787,600 shares, the days-to-cover ratio is currently 1.4 days.

Cue Biopharma Price Performance

CUE stock remained flat at $1.09 during midday trading on Thursday. 294,999 shares of the company's stock were exchanged, compared to its average volume of 449,430. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.22 and a current ratio of 2.22. The firm has a 50 day simple moving average of $1.25 and a two-hundred day simple moving average of $1.01. Cue Biopharma has a fifty-two week low of $0.45 and a fifty-two week high of $3.20. The firm has a market capitalization of $69.05 million, a P/E ratio of -1.21 and a beta of 1.66.

Insiders Place Their Bets

In other news, CEO Daniel R. Passeri bought 30,000 shares of the stock in a transaction dated Monday, December 16th. The shares were bought at an average cost of $1.03 per share, with a total value of $30,900.00. Following the completion of the transaction, the chief executive officer now directly owns 164,578 shares of the company's stock, valued at $169,515.34. This trade represents a 22.29 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 12.26% of the company's stock.

Institutional Investors Weigh In On Cue Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Cue Biopharma in the 2nd quarter valued at $66,000. GSA Capital Partners LLP grew its stake in shares of Cue Biopharma by 5.1% in the 3rd quarter. GSA Capital Partners LLP now owns 291,663 shares of the company's stock worth $221,000 after acquiring an additional 14,104 shares in the last quarter. Good Life Advisors LLC raised its holdings in shares of Cue Biopharma by 23.1% in the third quarter. Good Life Advisors LLC now owns 400,000 shares of the company's stock valued at $303,000 after purchasing an additional 75,000 shares during the last quarter. Sigma Planning Corp lifted its position in shares of Cue Biopharma by 50.9% during the third quarter. Sigma Planning Corp now owns 401,325 shares of the company's stock valued at $304,000 after purchasing an additional 135,295 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Cue Biopharma by 3.3% during the third quarter. Geode Capital Management LLC now owns 508,827 shares of the company's stock worth $385,000 after purchasing an additional 16,371 shares during the last quarter. 35.04% of the stock is owned by institutional investors.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.